Hostname: page-component-8448b6f56d-cfpbc Total loading time: 0 Render date: 2024-04-16T07:22:37.815Z Has data issue: false hasContentIssue false
  • English
  • Français

Venlafaxine and paroxetine in treatment-resistant depression

Double-blind, randomised comparison

Published online by Cambridge University Press:  03 January 2018

M.-F. Poirier  and
P. Boyer
M.-F. Poirier*
Affiliation:
SHU–Centre Hospitalier Sainte-Anne, Paris
P. Boyer
Affiliation:
Hôpital de la Pitié-Salpêtrière, Paris
*
Dr Marie-France Poirier, SHU-Centre Hospitalier Sainte-Anne, I, rue Cabanis, 75674 Paris, France. Tel: (33 I) 45 65 81 79; Fax: (33 I) 45 65 81 60
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

About one-third of patients fail to respond to initial antidepressant therapy, which suggests a need for more effective drugs.

Aims

To compare the efficacy and safety of venlafaxine and paroxetine in 122 patients with non-chronic treatment-resistant depression.

Method

In-patients or out-patients satisfying DSM – III – R criteria for major depression in evolution for less than eight months, having a baseline HAM–D score 18 and a HAM – D Item 3 score < 3 were eligible. Patients were required to have a history of resistance to two previous antidepressant treatments and a CGI improvement score of 3 at the beginning of treatment. Doses were adjusted to 200–300 mg/day for venlafaxine and 30–40 mg/day for paroxetine.

Results

For the observed-case analysis, the response rate was 51.9% for venlafaxine and 32.7% for paroxetine (P=0.044), and a remission was achieved in 42.3% of venlafaxine-treated and 20.0% of paroxetine-treated patients (P=0.01). The incidence of adverse effects was comparable between treatment groups.

Conclusions

Venlafaxine showed some evidence of superiority to paroxetine in this difficult-to-treat patient population.

Type
Papers
Information
The British Journal of Psychiatry , Volume 175 , Issue 1 , July 1999 , pp. 12 - 16
Copyright
Copyright © 1999 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Declaration of interest

Supported by a grant from Wyeth-Lederle, Paris, France.

References

Anderson, I. M. & Tomenson, B. M. (1994) The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. Journal of Psychopharmacology, 8, 238–249.CrossRefGoogle ScholarPubMed
Benkert, O., Gründer, G., Wetzel, H., et al (1996) A randomised double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. Journal of Psychiatric Research, 30, 441–451.Google Scholar
Benkert, O., Szegedi, A., Wetzel, H., et al (1997) Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with inadequate treatment response. Acta Psychiatrica Scandinavica, 95, 288–296.CrossRefGoogle ScholarPubMed
Clerc, G. E., Ruimy, P. & Verdeau-Paillès, J. (1994) A double-blind comparison of venlafaxine and fluoxetine in patients hospitalised for major depression and melancholia. International Clinical Psychopharmacology, 9, 139–143.Google Scholar
Danish University Antidepressant Group (1986) Citalopram: clinical effect profile in comparison with clomipramine; a controlled multicenter study. Psychopharmacology, 90, 131–138.Google Scholar
Danish University Antidepressant Group (1990) Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Journal of Affective Disorders, 18, 289–299.Google Scholar
Danjou, P. & Hackett, D. (1995) Safety and tolerance profile of venlafaxine. International Clinical Psychopharmacology, 10 (suppl. 2), 15–20.Google Scholar
de Montigny, C. (1999) Venlafaxine in treatment-resistant major depression: A Canadian multicentre open-label trial. Journal of Clinical Psychopharmacology, in press.CrossRefGoogle Scholar
Dierick, M., Ravizza, L., Realini, R., et al (1996) A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Progress in Neuropsychopharmacology and Biological Psychiatry, 20. 57–71.Google Scholar
Dinan, T. (1995) Treatment approaches to therapy-resistant depression. Journal of Psychopharmacology, 9 (suppl.), 199–204.Google Scholar
Dinan, T. & Burnett, F. (1997) Venlafaxine: pharmacology, clinical efficacy and tolerability of a serotonin– noradrenaline reuptake inhibitor. Journal of Serotonin Research, 3, 203–221.Google Scholar
Dunner, D. L. & Dunbar, G. C. (1992) Optimal dose regimen for paroxetine. Journal of Clinical Psychiatry, 53 (suppl. 2). 21–26.Google Scholar
Guelfi, J. D., White, C., Hackett, D., et al (1995) Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. Journal of Clinical Psychiatry, 56, 450–458.Google Scholar
Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacology Revised DHEW Pub. (ADM). Rockville. MD: National Institute of Mental Health.Google Scholar
Hamilton, M. (1960) A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry, 23, 56–62.CrossRefGoogle ScholarPubMed
Keller, M. B., Harrison, W., Fawcett, J. A., et al (1995) Treatment of chronic depression with sertraline or imipramine: preliminary blinded response rates and high rates of under treatment in the community. Psychopharmacology Bulletin, 31, 205–212.Google Scholar
Klerman, G. L., Weissman, M. M., Frank, E., et al (1994) Evaluating drug treatments of depressive disorders. In Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines (eds Prien, R. F. & Robinson, D. S.), pp. 281–325. New York: Raven Press.Google Scholar
Lecrubier, Y., Moon, C. A. L., Schifano, F., et al (1997) Double-blind, randomized, placebo-controlled comparison of venlafaxine and imipramine in general practice patients with mild to moderate depression. Acta Psychiatrica Scandinavica, 95, 485–493.Google Scholar
Lydiard, R. B. (1985) Tricyclic-resistant depression: Treatment resistant or inadequate treatment? Journal of Clinical Psychiatry, 46, 412–417.Google ScholarPubMed
Nierenberg, A. A., Feighner, J. P., Rudolph, R., et al (1994) Venlafaxine for treatment-resistant unipolar depression. Journal of Clinical Psycryopharmacology, 14, 419–423.Google ScholarPubMed
SAS Institute, Inc. (1989) SAS/STAT Release 6, User's Manual. Cary, NC: SAS Institute.Google Scholar
These, M. E. & Kupfer, D. J. (1987) Characteristics of treatment-resistant depression. In Treating Resistant Depression (eds Zohar, J. & Belmaker, R. H.), pp. 23–45. New York: PMA Publishing.Google Scholar
These, M. E., Rush, A. J., Kasper, S., et al (1995) Tricyclics and newer antidepressant medications: treatment options for treatment-resistant depressions. Depression, 2, 152–168.Google Scholar
Tylee, A., Beaumont, G., Bowden, M., et al (1997) A double-blind, randomised, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe depression in general practice. Primary Care Psychiatry, 3, 51–58.Google Scholar
Tyrer, P., Marsden, C. A., Casey, P., et al (1987) Clinical efficacy of paroxetine in resistant depression. Journal of Psychopharmacology, 1, 251–257.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.